Longevity A listers to decide on most innovative and translational longevity research projects – with the winners bagging $56,000.
Longevity.Technology: The Longevity Prize is awarded to translational longevity research projects that demonstrate exceptional potential to extend human healthspan and lifespan. It provides an excellent opportunity for researchers to showcase their work and contribute to the advancement of longevity research.
Contributed by Maximon, the three winners land prize money of CHF 50,000 ($ 56,000). However, since this is a longevity prize, Maximon ventures Biolytica and Avea are also rewarding the winners a personalized longevity concierge program valued at CHF 20,000 ($22,400) and CHF and a one-year subscription of longevity supplements valued at CHF 5,000 ($5,600).
The prize is open to any academic/non-profit scientist, innovator, student, or startup founder who has either published their breakthrough research, holds a patent, or is in very advanced stages of research.
Applications for the Maximon Longevity Prize 2023 will be accepted until June 30th, 2023; interested applicants are encouraged to submit their applications via the Maximon website.
Picking a winner
The projects will be judged by a panel of renowned experts in the field of longevity research who will evaluate their potential for translational impact.
The jury includes:
- Elisabeth Roider, MD, PhD, MBA, Chief Scientific & Medical Officer at Maximon
- Nir Barzilai, Director, Einstein Institute for Aging Research at Albert Einstein College of Medicine
- Aubrey de Grey, President and CSO at LEV Foundation
- Collin Ewald, Assistant Professor at ETH Zurich
- Evelyne Yehudit Bischof, Associate Professor at Shanghai University of Medicine and Health Sciences
- Andrea Maier, MD PhD FRACP, Oon Chiew Seng Professor in Medicine, Healthy Ageing and Dementia Research, Yong Loo Lin School of Medicine, National University of Singapore
- Heike Bischoff-Ferrari, Professor of Geriatrics and Aging Research at UZH
- Sebastien Thuault, Chief Editor at Nature Aging
- James Raaff, Co-Founder and Chief Program Officer at Biolytica AG
- Sophie Chabloz, Co-Founder & CPO at Avea Life
The winners will be honoured during the Longevity Investors Conference (LIC), which brings together leading scientists and investors, fostering collaboration and innovation in the field of longevity. The conference will take place on September 27-29th at Le Grand Bellevue Hotel in Gstaad, Switzerland.